

chain nodes :

18 19 20 21

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

chain bonds :

2-11 13-18 18-19 18-20 20-21

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 8-15 9-10 9-13 10-11 11-12 13-14 14-15

exact/norm bonds :

1-2 1-6 2-3 2-11 3-4 4-5 5-6 8-15 9-13 13-14 13-18 14-15 18-19 18-20 20-21

normalized bonds :

7-8 7-12 8-9 9-10 10-11 11-12

isolated ring systems :

containing 1 : 7 :

G1:C,O,N

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom  
12:Atom 13:Atom 14:Atom 15:Atom 18:CLASS 19:CLASS 20:CLASS 21:Atom

Generic attributes :

21:

Saturation : Unsaturated

10/089013

=> s l1

SAMPLE SEARCH INITIATED 12:40:26 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 338 TO ITERATE

100.0% PROCESSED 338 ITERATIONS  
SEARCH TIME: 00.00.01

16 ANSWERS

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 5657 TO 7863  
PROJECTED ANSWERS: 80 TO 560

L2 16 SEA SSS SAM L1

=> s l1 sss full

FULL SEARCH INITIATED 12:40:34 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 6709 TO ITERATE

100.0% PROCESSED 6709 ITERATIONS  
SEARCH TIME: 00.00.02

281 ANSWERS

L3 281 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

. 148.55

148.76

FILE 'CAPLUS' ENTERED AT 12:40:45 ON 06 MAY 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 6 May 2003 VOL 138 ISS 19

FILE LAST UPDATED: 5 May 2003 (20030505/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3

L4 7 L3


=> d l4 1-7 bib abs

10/089013


L4 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2003 ACS  
AN 2002:736250 CAPLUS  
DN 137:263062  
TI Preparation of piperazines as 5-HT1b receptor antagonist for the treatment of depression  
IN Thompson, Mervyn; Wyman, Paul Adrian  
PA Smithkline Beecham P.L.C., UK  
SO PCT Int. Appl., 24 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

*Later*

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002074764	A2	20020926	WO 2002-EP2632	20020311
	WO 2002074764	A3	20021114		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRAI	GB 2001-6419	A	20010315		
OS	MARPAT 137:263062				
GI					



I



II

AB Title compds. I [Ra = R1(R2)bP2-(R3)cP3- where P2 = Ph, naphthyl, heteroaryl, etc. and P3 = Ph, naphthyl, heteroaryl and R1 = NR4COR5, NR4SO2R5, CH2NR4SO2R5, etc. and R2, R3 = halo, alkyl, cycloalkyl, etc; Rb = H, halo, alkyl, etc.; Rc = H, alkyl; R4, R5 = H, alkyl; b, c = 0-3; Y = single bond, CH2, NH; W = CH=CH, -(CR9R10)t- where t = 2-4 and R9, R10 = H, alkyl] and their pharmaceutically acceptable salts were prepd. For

example, coupling of cis-6-(3,5-dimethylpiperazin-1-yl)-5-methoxyindoline, e.g., prepd. from 1-acetyl-6-bromo-5-methoxyindoline in 3-steps, and Me 4-(6-acetamido-2-methylpyridin-3-yl)benzoate afforded piperazine II in 82% yield. In radioligand binding assays, all examples tested were found to have a  $pK_i > 7.0$  at 5-HT<sub>1b</sub> receptors with many demonstrating a  $pK_i$  in the higher range of 8.0-8.5. All examples tested were found to have a greater than a 10-fold selectivity over 5-HT<sub>1d</sub> receptors and a greater than 50-fold selectivity over other binding sites within the CNS, in particular, other 5-HT receptor subtypes and dopaminergic receptors. Many examples were found to have a greater than a 30-fold selectivity over 5-HT<sub>1d</sub> receptors and a greater than 80-fold selectivity over other binding sites.

IT 461658-03-7P, cis-1-[4-(6-Acetamido-2-methylpyridin-3-yl)benzoyl]-6-(3,5-dimethylpiperazin-1-yl)-5-methoxyindoline 461658-04-8P, cis-1-(4'-Acetamido-2'-methylbiphenyl-4-carbonyl)-6-(3,5-dimethylpiperazin-1-yl)-5-fluoroindole 461658-05-9P 461658-06-0P 461658-07-1P 461658-08-2P 461658-09-3P 461658-10-6P 461658-11-7P 461658-12-8P 461658-13-9P 461658-14-0P 461658-15-1P 461658-16-2P 461658-17-3P 461658-18-4P 461658-19-5P 461658-20-8P 461658-21-9P 461658-22-0P 461658-23-1P 461658-24-2P 461658-25-3P 461658-26-4P 461658-27-5P 461658-28-6P 461658-29-7P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; prepn. of piperazines as 5-HT<sub>1b</sub> receptor antagonist for the treatment of depression)

RN 461658-03-7 CAPLUS

CN Acetamide, N-[5-[4-[[6-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-2,3-dihydro-5-methoxy-1H-indol-1-yl]carbonyl]phenyl]-6-methyl-2-pyridinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 461658-04-8 CAPLUS

CN Acetamide, N-[4'-[[6-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-5-fluoro-1H-indol-1-yl]carbonyl]-2-methyl[1,1'-biphenyl]-4-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


10/089013



RN 461658-05-9 CAPLUS

CN 1H-Indole, 6-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-2,3-dihydro-5-methoxy-1-[4-[2-methyl-6-[(methylsulfonyl)amino]-3-pyridinyl]benzoyl]-, rel- (9CI)  
(CA INDEX NAME)

Relative stereochemistry.




RN 461658-06-0 CAPLUS

CN Acetamide, N-[5-[4-[[6-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-2,3-dihydro-5-methoxy-1H-indol-1-yl]carbonyl]phenyl]-6-methyl-2-pyridinyl]-N-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


10/089013



RN 461658-07-1 CAPLUS

CN 1H-Indole, 6-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-2,3-dihydro-5-methoxy-1-[4-[2-methyl-6-[methyl(methylsulfonyl)amino]-3-pyridinyl]benzoyl]-, rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 461658-08-2 CAPLUS

CN 1H-Indole, 6-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-5-fluoro-2,3-dihydro-1-[4-[2-methyl-6-[methyl(methylsulfonyl)amino]-3-pyridinyl]benzoyl]-, rel-(9CI). (CA INDEX NAME)

Relative stereochemistry.


10/089013



RN 461658-09-3 CAPLUS

CN Acetamide, N-[4'-[[6-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-2,3-dihydro-5-methoxy-1H-indol-1-yl]carbonyl]-2-methyl[1,1'-biphenyl]-4-yl]-, rel- (9CI)  
(CA INDEX NAME)

Relative stereochemistry.




RN 461658-10-6 CAPLUS

CN 1H-Indole, 6-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-2,3-dihydro-5-methoxy-1-[[2'-methyl-4'-[(methylsulfonyl)amino][1,1'-biphenyl]-4-yl]carbonyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


10/089013



RN 461658-11-7 CAPLUS

CN Acetamide, N-[4'-[[6-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-5-fluoro-2,3-dihydro-1H-indol-1-yl]carbonyl]-2-methyl[1,1'-biphenyl]-4-yl]-, rel- (9CI)  
(CA INDEX NAME)


Relative stereochemistry.



RN 461658-12-8 CAPLUS

CN 1H-Indole, 6-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-5-fluoro-2,3-dihydro-1-[[2'-methyl-4'-[(methylsulfonyl)amino][1,1'-biphenyl]-4-yl]carbonyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 461658-13-9 CAPLUS

CN Acetamide, N-[[4'-[[6-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-2,3-dihydro-5-methoxy-1H-indol-1-yl]carbonyl]-2-methyl[1,1'-biphenyl]-4-yl]methyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 461658-14-0 CAPLUS

CN Acetamide, N-[[4'-[[6-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-2,3-dihydro-5-methyl-1H-indol-1-yl]carbonyl]-2-methyl[1,1'-biphenyl]-4-yl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




10/089013

RN 461658-15-1 CAPLUS

CN Acetamide, N-[[4'-[[6-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-5-fluoro-2,3-dihydro-1H-indol-1-yl]carbonyl]-2-methyl[1,1'-biphenyl]-4-yl]methyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 461658-16-2 CAPLUS

CN Acetamide, N-[[4'-[[5-chloro-6-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-2,3-dihydro-1H-indol-1-yl]carbonyl]-2-methyl[1,1'-biphenyl]-4-yl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 461658-17-3 CAPLUS

CN 1H-Indole, 6-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-5-fluoro-1-[[2'-methyl-4'-[(methylsulfonyl)amino][1,1'-biphenyl]-4-yl]carbonyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


10/089013



RN 461658-18-4 CAPLUS

CN 1H-Indole, 6-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-5-fluoro-1-[4-[2-methyl-6-[methyl(methylsulfonyl)amino]-3-pyridinyl]benzoyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 461658-19-5 CAPLUS

CN Acetamide, N-[[4'-[[6-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-5-fluoro-1H-indol-1-yl]carbonyl]-2-methyl[1,1'-biphenyl]-4-yl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


10/089013



RN 461658-20-8 CAPLUS

CN Acetamide, N-[[4'-[[5-chloro-6-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-1H-indol-1-yl]carbonyl]-2-methyl[1,1'-biphenyl]-4-yl]methyl]-, rel- (9CI)  
(CA INDEX NAME)


Relative stereochemistry.



RN 461658-21-9 CAPLUS

CN Acetamide, N-[[4'-[[6-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-5-methyl-1H-indol-1-yl]carbonyl]-2-methyl[1,1'-biphenyl]-4-yl]methyl]-, rel- (9CI)  
(CA INDEX NAME)

Relative stereochemistry.




10/089013

RN 461658-22-0 CAPLUS

CN Acetamide, N-[5-[4-[[6-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-5-fluoro-1H-indol-1-yl]carbonyl]phenyl]-6-methyl-2-pyridinyl]-N-methyl-, rel- (9CI)  
(CA INDEX NAME)


Relative stereochemistry.



RN 461658-23-1 CAPLUS

CN 1H-Indole, 6-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-5-fluoro-2,3-dihydro-1-[4-[2-methyl-6-[(methylsulfonyl)amino]-3-pyridinyl]benzoyl]-, rel- (9CI)  
(CA INDEX NAME)

Relative stereochemistry.




RN 461658-24-2 CAPLUS

CN Acetamide, N-[5-[4-[[6-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-5-fluoro-2,3-dihydro-1H-indol-1-yl]carbonyl]phenyl]-6-methyl-2-pyridinyl]-, rel- (9CI)  
(CA INDEX NAME)

Relative stereochemistry.


10/089013



RN 461658-25-3 CAPLUS

CN Acetamide, N-[5-[4-[[6-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-5-fluoro-2,3-dihydro-1H-indol-1-yl]carbonyl]phenyl]-6-methyl-2-pyridinyl]-N-methyl-,  
rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 461658-26-4 CAPLUS

CN 1H-Indole, 6-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-5-fluoro-2,3-dihydro-1-  
[[2'-methyl-4'-[methyl(methylsulfonyl)amino][1,1'-biphenyl]-4-yl]carbonyl]-  
, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 461658-27-5 CAPLUS

CN Acetamide, N-[4'-[[6-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-5-fluoro-2,3-dihydro-1H-indol-1-yl]carbonyl]-2-methyl[1,1'-biphenyl]-4-yl]-N-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 461658-28-6 CAPLUS

CN Acetamide, N-[4'-[[2,3-dihydro-5-methoxy-6-[(3R,5S)-3,4,5-trimethyl-1-piperazinyl]-1H-indol-1-yl]carbonyl]-2-methyl[1,1'-biphenyl]-4-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


10/089013



RN 461658-29-7 CAPLUS


CN Acetamide, N-[[[4'-[[[2,3-dihydro-5-methoxy-6-[(3R,5S)-3,4,5-trimethyl-1-piperazinyl]-1H-indol-1-yl]carbonyl]-2-methyl[1,1'-biphenyl]-4-yl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2003 ACS  
AN 2001:561564 CAPLUS  
DN 135:236345  
TI SB-272183, a selective 5-HT1A, 5-HT1B and 5-HT1D receptor antagonist in native tissue.  
AU Watson, J.; Roberts, C.; Scott, C.; Kendall, I.; Collin, L.; Day, N. C.; Harries, M. H.; Soffin, E.; Davies, C. H.; Randall, A. D.; Heightman, T.; Gaster, L.; Wyman, P.; Parker, C.; Price, G. W.; Middlemiss, D. N.  
CS Neuroscience Research and Department of Medicinal Chemistry, GlaxoSmithKline, New Frontiers Science Park, Essex, CM19 5AW, UK  
SO British Journal of Pharmacology (2001), 133(6), 797-806  
CODEN: BJPCBM; ISSN: 0007-1188  
PB Nature Publishing Group  
DT Journal  
LA English  
AB A novel compd., SB-272183, has been shown to have high affinity for human 5-HT1A, 5-HT1B and 5-HT1D receptors with pKi values of 8.0, 8.1 and 8.7 resp. and is at least 30 fold selective over a range of other receptors. [35S]-GTP.gamma.S binding studies showed that SB-272183 acts as a partial agonist at human recombinant 5-HT1A, 5-HT1B and 5-HT1D receptors with intrinsic activities of 0.4, 0.4 and 0.8 resp., compared to 5-HT. SB-272183 inhibited 5-HT-induced stimulation of [35S]-GTP.gamma.S binding at human 5-HT1A and 5-HT1B receptors to give pA2 values of 8.2 and 8.5 resp. However, from [35S]-GTP.gamma.S autoradiog. studies in rat and human dorsal raphe nucleus, SB-272183 did not display intrinsic activity up to 10 .mu.M but did block 5-HT-induced stimulation of [35S]-GTP.gamma.S binding. From electrophysiol. studies in rat raphe slices in vitro, SB-272183 did not effect cell firing rate up to 1 .mu.M but was able to attenuate (+)8-OH-DPAT-induced inhibition of cell firing to give an apparent pKb of 7.1. SB-272183 potentiated elec.-stimulated [3H]-5-HT release from rat and guinea pig cortical slices at 100 and 1000 nM, similar to results previously obtained with the 5-HT1B and 5-HT1D receptor antagonist, GR 127935. Fast cyclic voltammetry studies in rat dorsal raphe nucleus showed that SB-272183 could block sumatriptan-induced inhibition of 5-HT efflux, with an apparent pKb of 7.2, but did not effect basal efflux up to 1 .mu.M. These studies show that, in vitro, SB-272183 acts as an antagonist at native tissue 5-HT1A, 5-HT1B and 5-HT1D receptors.  
IT 216058-27-4, SB 272183  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)  
(SB-272183 as selective 5-HT1A and 5-HT1B and 5-HT1D receptor antagonist in native tissue)  
RN 216058-27-4 CAPLUS  
CN 1H-Indole-1-carboxamide, 5-chloro-2,3-dihydro-6-(4-methyl-1-piperazinyl)-N-[4-(4-pyridinyl)-1-naphthalenyl]- (9CI) (CA INDEX NAME)

10/089013




RE.CNT 38      THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/089013

L4 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2003 ACS  
AN 2001:247327 CAPLUS  
DN 134:280860  
TI Preparation of piperazine derivatives as 5-HT1B antagonists  
IN Marshall, Howard; Thompson, Mervyn; Wyman, Paul Adrian  
PA Smithkline Beecham P.L.C., UK  
SO PCT Int. Appl., 37 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

APPS PCT

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001023374	A1	20010405	WO 2000-EP9442	20000921
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	BR 2000014279	A	20020521	BR 2000-14279	20000921
	EP 1216239	A1	20020626	EP 2000-967803	20000921
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
	JP 2003510317	T2	20030318	JP 2001-526526	20000921
	NO 2002001459	A	20020322	NO 2002-1459	20020322
PRAI	GB 1999-22831	A	19990925		
	GB 2000-1936	A	20000127		
	GB 2000-13873	A	20000607		
	WO 2000-EP9442	W	20000921		
OS	MARPAT 134:280860				
GI					



AB Piperazine derivs. I [Ra = R1aP1 where P1 = Ph, naphthyl, heteroaryl and R1 = halo, alkyl, cycloalkyl, etc.; Rb = H, halo, OH, alkyl, etc.; Rc = H, alkyl; Rd, Re = alkyl; Y = bond, CH2, O, NR5; W = (CR9R10)t where t = 2-4 and R9 and R10 = H, alkyl or W = CH:CH], 5-HT1B antagonists, were prepd.. All examples tested in the radioligand binding assay were found to have a pKi > 7.3 at 5-HT1B receptors with many demonstrating a pKi in the higher range of 8.0-9.2. E.g., cis-5-methoxy-1-[4-(6-methylpyridin-2-yl)-1-

10/089013

naphthoyl]-6-(3,4,5-trimethylpiperazin-1-yl)indoline was prepd.

IT 332397-37-2P 332397-40-7P 332397-49-6P

332397-60-1P 332397-62-3P 332397-67-8P

332397-68-9P 332397-89-4P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(prepn. of piperazine derivs. as 5-HT1B antagonists)

RN 332397-37-2 CAPLUS

CN 1H-Indole, 1-[[2-chloro-3-(trifluoromethyl)phenyl]acetyl]-2,3-dihydro-6-[(3R,5S)-3,4,5-trimethyl-1-piperazinyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 332397-40-7 CAPLUS

CN 1H-Indole, 1-[(2,3-dichlorophenyl)acetyl]-6-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-2,3-dihydro-5-methoxy-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 332397-49-6 CAPLUS

CN 1H-Indole, 2,3-dihydro-5-methoxy-1-[[4-(6-methyl-2-pyridinyl)-1-naphthalenyl]acetyl]-6-[(3R,5S)-3,4,5-trimethyl-1-piperazinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


10/089013



RN 332397-60-1 CAPLUS

CN 1H-Indole, 1-[(3-chloro-2-fluorophenyl)acetyl]-6-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-2,3-dihydro-5-methoxy-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 332397-62-3 CAPLUS

CN 1H-Indole, 5-fluoro-1-[[2-fluoro-3-(trifluoromethyl)phenyl]acetyl]-2,3-dihydro-6-[(3R,5S)-3,4,5-trimethyl-1-piperazinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


10/089013



RN 332397-67-8 CAPLUS

CN 1H-Indole, 1-[(3-cyano-2-methylphenyl)acetyl]-2,3-dihydro-5-methoxy-6-[(3R,5S)-3,4,5-trimethyl-1-piperazinyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 332397-68-9 CAPLUS

CN 1H-Indole, 5-bromo-1-[[2-chloro-3-(trifluoromethyl)phenyl]acetyl]-2,3-dihydro-6-[(3R,5S)-3,4,5-trimethyl-1-piperazinyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 332397-89-4 CAPLUS

CN 1H-Indole-1-carboxamide, N-(2,3-dichlorophenyl)-2,3-dihydro-5-methoxy-6-[(3R,5S)-3,4,5-trimethyl-1-piperazinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 332397-16-7P 332397-21-4P 332397-25-8P  
 332397-29-2P 332397-30-5P 332397-32-7P  
 332397-35-0P 332397-39-4P 332397-41-8P  
 332397-42-9P 332397-43-0P 332397-44-1P  
 332397-45-2P 332397-46-3P 332397-47-4P  
 332397-48-5P 332397-50-9P 332397-51-0P  
 332397-52-1P 332397-53-2P 332397-54-3P  
 332397-55-4P 332397-56-5P 332397-57-6P  
 332397-58-7P 332397-59-8P 332397-61-2P  
 332397-63-4P 332397-64-5P 332397-65-6P  
 332397-66-7P 332397-69-0P 332397-70-3P  
 332397-71-4P 332397-72-5P 332397-73-6P  
 332397-74-7P 332397-75-8P 332397-76-9P  
 332397-77-0P 332397-78-1P 332397-79-2P  
 332397-80-5P 332397-81-6P 332397-82-7P  
 332397-83-8P 332397-84-9P 332397-85-0P  
 332397-86-1P 332397-87-2P 332397-88-3P  
 332397-90-7P 332397-91-8P 332397-92-9P  
 332397-93-0P 332397-94-1P 332397-95-2P  
 332397-96-3P 332397-97-4P 332397-98-5P  
 332397-99-6P 332398-00-2P 332398-01-3P  
 332398-02-4P 332398-03-5P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of piperazine derivs. as 5-HT<sub>1B</sub> antagonists)

RN 332397-16-7 CAPLUS

CN 1H-Indole, 2,3-dihydro-5-methoxy-1-[[4-(6-methyl-2-pyridinyl)-1-naphthalenyl]carbonyl]-6-[(3R,5S)-3,4,5-trimethyl-1-piperazinyl]-, rel-  
 (9CI) (CA INDEX NAME)

Relative stereochemistry.


10/089013



RN 332397-21-4 CAPLUS

CN 1H-Indole, 2,3-dihydro-5-methoxy-1-[[5-(6-methyl-2-pyridinyl)-1-naphthalenyl]carbonyl]-6-[(3R,5S)-3,4,5-trimethyl-1-piperazinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 332397-25-8 CAPLUS

CN 1H-Indole, 2,3-dihydro-5-methoxy-1-[[5-(2-methyl-5-oxazolyl)-1-naphthalenyl]carbonyl]-6-[(3R,5S)-3,4,5-trimethyl-1-piperazinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


10/089013



RN 332397-29-2 CAPLUS

CN 1H-Indole, 1-(2,3-dichlorobenzoyl)-2,3-dihydro-5-methoxy-6-[(3R,5S)-3,4,5-trimethyl-1-piperazinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 332397-30-5 CAPLUS

CN 1H-Indole, 2,3-dihydro-5-methoxy-1-[[2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)[1,1'-biphenyl]-4-yl]carbonyl]-6-[(3R,5S)-3,4,5-trimethyl-1-piperazinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


10/089013



RN 332397-32-7 CAPLUS

CN 1H-Indole, 2,3-dihydro-5-methoxy-1-[(3-nitrophenyl)acetyl]-6-[(3R,5S)-3,4,5-trimethyl-1-piperazinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 332397-35-0 CAPLUS

CN Quinoline, 1,2,3,4-tetrahydro-6-methoxy-1-[[4-(6-methyl-2-pyridinyl)-1-naphthalenyl]carbonyl]-7-[(3R,5S)-3,4,5-trimethyl-1-piperazinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


10/089013



RN 332397-39-4 CAPLUS

CN 1H-Indole, 1-[[2-fluoro-3-(trifluoromethyl)phenyl]acetyl]-2,3-dihydro-5-methoxy-6-[(3R,5S)-3,4,5-trimethyl-1-piperazinyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 332397-41-8 CAPLUS

CN 1H-Indole, 1-[(3-chloro-2-fluorophenyl)acetyl]-2,3-dihydro-6-[(3R,5S)-3,4,5-trimethyl-1-piperazinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




10/089013

RN 332397-42-9 CAPLUS

CN 1H-Indole, 1-[(2,3-difluorophenyl)acetyl]-2,3-dihydro-6-[(3R,5S)-3,4,5-trimethyl-1-piperazinyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 332397-43-0 CAPLUS

CN 1H-Indole, 1-[(2,3-dichlorophenyl)acetyl]-2,3-dihydro-6-[(3R,5S)-3,4,5-trimethyl-1-piperazinyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 332397-44-1 CAPLUS

CN 1H-Indole, 2,3-dihydro-1-[[2-(trifluoromethyl)phenyl]acetyl]-6-[(3R,5S)-3,4,5-trimethyl-1-piperazinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry..




RN 332397-45-2 CAPLUS

CN 1H-Indole, 1-[(2,3-dichlorophenyl)acetyl]-2,3-dihydro-5-methoxy-6-[(3R,5S)-3,4,5-trimethyl-1-piperazinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


10/089013



RN 332397-46-3 CAPLUS

CN 1H-Indole, 2,3-dihydro-5-methoxy-1-[[2-(trifluoromethyl)phenyl]acetyl]-6-[(3R,5S)-3,4,5-trimethyl-1-piperazinyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 332397-47-4 CAPLUS

CN 1H-Indole, 1-[(3-chloro-2-fluorophenyl)acetyl]-2,3-dihydro-5-methoxy-6-[(3R,5S)-3,4,5-trimethyl-1-piperazinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 332397-48-5 CAPLUS

CN 1H-Indole, 1-[(2,3-difluorophenyl)acetyl]-2,3-dihydro-5-methoxy-6-[(3R,5S)-3,4,5-trimethyl-1-piperazinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


10/089013



RN 332397-50-9 CAPLUS

CN 1H-Indole, 5-chloro-2,3-dihydro-1-[[4-(6-methyl-2-pyridinyl)-1-naphthalenyl]carbonyl]-6-[(3R,5S)-3,4,5-trimethyl-1-piperazinyl]-, rel- (9CI) . (CA INDEX NAME)

Relative stereochemistry.




RN 332397-51-0 CAPLUS

CN 1H-Indole, 1-[[4-(2,6-dimethyl-3-pyridinyl)-1-naphthalenyl]carbonyl]-2,3-dihydro-5-methoxy-6-[(3R,5S)-3,4,5-trimethyl-1-piperazinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


10/089013



RN 332397-52-1 CAPLUS

CN 1H-Indole, 1-[[4-(3,6-dimethylpyrazinyl)-1-naphthalenyl]carbonyl]-2,3-dihydro-5-methoxy-6-[(3R,5S)-3,4,5-trimethyl-1-piperazinyl]-, rel- (9CI)  
(CA INDEX NAME)

Relative stereochemistry.




RN 332397-53-2 CAPLUS

CN 1H-Indole, 1-[[4-(1,6-dihydro-1-methyl-6-oxo-3-pyridinyl)-1-naphthalenyl]carbonyl]-2,3-dihydro-5-methoxy-6-[(3R,5S)-3,4,5-trimethyl-1-piperazinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


10/089013



RN 332397-54-3 CAPLUS

CN 1H-Indole, 1-[[2-fluoro-3-(trifluoromethyl)phenyl]acetyl]-2,3-dihydro-5-methyl-6-[(3R,5S)-3,4,5-trimethyl-1-piperazinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 332397-55-4 CAPLUS

CN 1H-Indole, 1-[(2-chloro-3-fluorophenyl)acetyl]-2,3-dihydro-5-methoxy-6-[(3R,5S)-3,4,5-trimethyl-1-piperazinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


10/089013



RN 332397-56-5 CAPLUS

CN 1H-Indole, 1-[(2-bromo-3-fluorophenyl)acetyl]-2,3-dihydro-5-methoxy-6-[(3R,5S)-3,4,5-trimethyl-1-piperazinyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 332397-57-6 CAPLUS

CN 1H-Indole, 1-[(2-bromo-3-chlorophenyl)acetyl]-2,3-dihydro-5-methoxy-6-[(3R,5S)-3,4,5-trimethyl-1-piperazinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 332397-58-7 CAPLUS

CN 1H-Indole, 6-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-1-[[2-fluoro-3-(trifluoromethyl)phenyl]acetyl]-2,3-dihydro-5-methoxy-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.

10/089013




RN 332397-59-8 CAPLUS  
CN 1H-Indole, 1-[[2-chloro-3-(trifluoromethyl)phenyl]acetyl]-6-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-2,3-dihydro-5-methoxy-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 332397-61-2 CAPLUS  
CN 1H-Indole, 1-[[2-chloro-3-(trifluoromethyl)phenyl]acetyl]-2,3-dihydro-5-methoxy-6-[(3R,5S)-3,4,5-trimethyl-1-piperazinyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 332397-63-4 CAPLUS  
CN 1H-Indole, 1-[[3-fluoro-2-(trifluoromethyl)phenyl]acetyl]-2,3-dihydro-5-methoxy-6-[(3R,5S)-3,4,5-trimethyl-1-piperazinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


10/089013



RN 332397-64-5 CAPLUS

CN 1H-Indole, 1-[(3-chloro-2-cyanophenyl)acetyl]-2,3-dihydro-5-methoxy-6-[(3R,5S)-3,4,5-trimethyl-1-piperazinyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 332397-65-6 CAPLUS

CN 1H-Indole, 1-[(2-acetyl-3-chlorophenyl)acetyl]-2,3-dihydro-5-methoxy-6-[(3R,5S)-3,4,5-trimethyl-1-piperazinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 332397-66-7 CAPLUS

CN 1H-Indole, 1-[(3-bromo-2-methylphenyl)acetyl]-2,3-dihydro-5-methoxy-6-[(3R,5S)-3,4,5-trimethyl-1-piperazinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


10/089013



RN 332397-69-0 CAPLUS

CN 1H-Indole, 5-acetyl-1-[[2-chloro-3-(trifluoromethyl)phenyl]acetyl]-2,3-dihydro-6-[(3R,5S)-3,4,5-trimethyl-1-piperazinyl]-, rel- (9CI). (CA INDEX NAME)


Relative stereochemistry.



RN 332397-70-3 CAPLUS

CN 1H-Indole, 2,3-dihydro-5-methoxy-1-[[1-phenyl-5-(trifluoromethyl)-1H-pyrazol-4-yl]carbonyl]-6-[(3R,5S)-3,4,5-trimethyl-1-piperazinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 332397-71-4 CAPLUS

CN 1H-Indole, 6-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-2,3-dihydro-5-methoxy-1-[[2'-methyl-4'-(2-oxo-1-pyrrolidinyl)[1,1'-biphenyl]-4-yl]carbonyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


10/089013



RN 332397-72-5 CAPLUS

CN 1H-Indole, 6-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-2,3-dihydro-5-methoxy-1-  
[[2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)[1,1'-biphenyl]-4-  
yl]carbonyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 332397-73-6 CAPLUS

CN 1H-Indole, 6-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-2,3-dihydro-5-methoxy-1-  
[4-[2-methyl-6-(2-oxo-1-pyrrolidinyl)-3-pyridinyl]benzoyl]-, rel- (9CI)  
(CA INDEX NAME)

Relative stereochemistry.


10/089013



RN 332397-74-7 CAPLUS

CN 1H-Indole, 6-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-2,3-dihydro-5-methoxy-1-[[4-(6-methyl-2-pyridinyl)-1-naphthalenyl]carbonyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 332397-75-8 CAPLUS

CN 1H-Indole-5-carbonitrile, 1-[[2-chloro-3-(trifluoromethyl)phenyl]acetyl]-2,3-dihydro-6-[(3R,5S)-3,4,5-trimethyl-1-piperazinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


10/089013



RN 332397-76-9 CAPLUS

CN Benzamide, 3-[2-[2,3-dihydro-5-methoxy-6-[(3R,5S)-3,4,5-trimethyl-1-piperazinyl]-1H-indol-1-yl]-2-oxoethyl]-2-methyl-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 332397-77-0 CAPLUS

CN 1H-Indole, 2,3-dihydro-5-methoxy-1-[[4-(1-methyl-4-piperidiny)-1-naphthalenyl]carbonyl]-6-[(3R,5S)-3,4,5-trimethyl-1-piperazinyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 332397-78-1 CAPLUS

CN 1H-Indole, 2,3-dihydro-5-methoxy-1-[[4-(4-piperidinyl)-1-naphthalenyl]carbonyl]-6-[(3R,5S)-3,4,5-trimethyl-1-piperazinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 332397-79-2 CAPLUS

CN 1H-Indole, 1-[[2-chloro-3-(trifluoromethyl)phenyl]acetyl]-6-[(3R,5S)-3,4,5-trimethyl-1-piperazinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


10/089013



RN 332397-80-5 CAPLUS

CN 1H-Indole, 1-[[2-fluoro-3-(trifluoromethyl)phenyl]acetyl]-5-methoxy-6-[(3R,5S)-3,4,5-trimethyl-1-piperazinyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 332397-81-6 CAPLUS

CN 1H-Indole-1-carboxamide, N-(2,3-dichlorophenyl)-5-methoxy-6-[(3R,5S)-3,4,5-trimethyl-1-piperazinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 332397-82-7 CAPLUS

CN 1H-Indole, 5-methoxy-1-[[4-(6-methyl-2-pyridinyl)-1-naphthalenyl]acetyl]-6-[(3R,5S)-3,4,5-trimethyl-1-piperazinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


10/089013



RN 332397-83-8 CAPLUS

CN 1H-Indole, 1-[(3-chloro-2-fluorophenyl)acetyl]-6-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-5-methoxy-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 332397-84-9 CAPLUS

CN 1H-Indole, 1-[(2,3-dichlorophenyl)acetyl]-6-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-5-methoxy-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




10/089013

RN 332397-85-0 CAPLUS

CN 1H-Indole, 5-fluoro-1-[[2-fluoro-3-(trifluoromethyl)phenyl]acetyl]-6-  
[(3R,5S)-3,4,5-trimethyl-1-piperazinyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 332397-86-1 CAPLUS

CN 1H-Indole-1-carboxamide, 2,3-dihydro-5-methoxy-N-[4-(6-methyl-2-pyridinyl)-  
1-naphthalenyl]-6-[(3R,5S)-3,4,5-trimethyl-1-piperazinyl]-, rel- (9CI)  
(CA INDEX NAME)

Relative stereochemistry.




RN 332397-87-2 CAPLUS

CN 1H-Indole-1-carboxamide, 2,3-dihydro-5-methoxy-N-[5-(6-methyl-2-pyridinyl)-  
1-naphthalenyl]-6-[(3R,5S)-3,4,5-trimethyl-1-piperazinyl]-, rel- (9CI)  
(CA INDEX NAME)

Relative stereochemistry.


10/089013



RN 332397-88-3 CAPLUS

CN 1H-Indole-1-carboxamide, 2,3-dihydro-5-methoxy-N-[5-(2-methyl-5-oxazolyl)-1-naphthalenyl]-6-[(3R,5S)-3,4,5-trimethyl-1-piperazinyl]-, rel- (9CI)  
(CA INDEX NAME)

Relative stereochemistry.




RN 332397-90-7 CAPLUS

CN 1H-Indole-1-carboxamide, N-(3-chloro-2-fluorophenyl)-2,3-dihydro-5-methoxy-6-[(3R,5S)-3,4,5-trimethyl-1-piperazinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


10/089013



RN 332397-91-8 CAPLUS

CN 1H-Indole-1-carboxamide, N-[3-fluoro-2-(trifluoromethyl)phenyl]-2,3-dihydro-5-methoxy-6-[(3R,5S)-3,4,5-trimethyl-1-piperazinyl]-, rel- (9CI)  
(CA INDEX NAME)


Relative stereochemistry.



RN 332397-92-9 CAPLUS

CN 1H-Indole-1-carboxamide, N-[2-chloro-3-(trifluoromethyl)phenyl]-2,3-dihydro-5-methoxy-6-[(3R,5S)-3,4,5-trimethyl-1-piperazinyl]-, rel- (9CI)  
(CA INDEX NAME)

Relative stereochemistry.




RN 332397-93-0 CAPLUS

CN 1H-Indole-1-carboxamide, N-(2-chloro-3-methylphenyl)-2,3-dihydro-5-methoxy-6-[(3R,5S)-3,4,5-trimethyl-1-piperazinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


10/089013



RN 332397-94-1 CAPLUS

CN 1H-Indole-1-carboxamide, N-[2-chloro-3-(trifluoromethyl)phenyl]-2,3-dihydro-5-methyl-6-[(3R,5S)-3,4,5-trimethyl-1-piperazinyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 332397-95-2 CAPLUS

CN 1H-Indole-1-carboxamide, N-(2,3-dichlorophenyl)-2,3-dihydro-6-[(3R,5S)-3,4,5-trimethyl-1-piperazinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 332397-96-3 CAPLUS

CN 1H-Indole-1-carboxamide, 5-chloro-N-(2,3-dichlorophenyl)-2,3-dihydro-6-[(3R,5S)-3,4,5-trimethyl-1-piperazinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


10/089013



RN 332397-97-4 CAPLUS

CN 1H-Indole-1-carboxamide, 5-bromo-N-(2,3-dichlorophenyl)-2,3-dihydro-6-[(3R,5S)-3,4,5-trimethyl-1-piperazinyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 332397-98-5 CAPLUS

CN 1H-Indole-1-carboxamide, N-(2,3-dichlorophenyl)-5-ethyl-2,3-dihydro-6-[(3R,5S)-3,4,5-trimethyl-1-piperazinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 332397-99-6 CAPLUS

CN 1H-Indole-1-carboxamide, 2,3-dihydro-5-methoxy-N-[2-(trifluoromethyl)phenyl]-6-[(3R,5S)-3,4,5-trimethyl-1-piperazinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


10/089013



RN 332398-00-2 CAPLUS

CN 1H-Indole-1-carboxamide, N-[2-fluoro-3-(trifluoromethyl)phenyl]-2,3-dihydro-5-methoxy-6-[(3R,5S)-3,4,5-trimethyl-1-piperazinyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 332398-01-3 CAPLUS

CN 1H-Indole-1-carboxamide, N-[2-chloro-3-(trifluoromethyl)phenyl]-2,3-dihydro-5-methoxy-3,3-dimethyl-6-[(3R,5S)-3,4,5-trimethyl-1-piperazinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 332398-02-4 CAPLUS

CN 1H-Indole-1-carboxylic acid, 2,3-dihydro-5-methoxy-6-[(3R,5S)-3,4,5-trimethyl-1-piperazinyl]-, 2-chloro-3-(trifluoromethyl)phenyl ester, rel- (9CI) (CA INDEX NAME)

10/089013


Relative stereochemistry.



RN 332398-03-5 CAPLUS

CN 1H-Indole-1-carboxamide, N-[2-chloro-3-(trifluoromethyl)phenyl]-5-methyl-6-[(3R,5S)-3,4,5-trimethyl-1-piperazinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 332398-22-8P 332398-39-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(prepn. of piperazine derivs. as 5-HT1B antagonists)

RN 332398-22-8 CAPLUS

CN 1H-Indole, 6-[(3R,5S)-3,5-dimethyl-4-(phenylmethyl)-1-piperazinyl]-2,3-dihydro-5-methoxy-1-[[4-(6-methyl-2-pyridinyl)-1-naphthalenyl]carbonyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


10/089013



RN 332398-39-7 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[4-[[2,3-dihydro-5-methoxy-6-[(3R,5S)-3,4,5-trimethyl-1-piperazinyl]-1H-indol-1-yl]carbonyl]-1-naphthalenyl]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 332399-40-3P 332399-42-5P


RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of piperazine derivs. as 5-HT1B antagonists)

RN 332399-40-3 CAPLUS

CN 1H-Indole, 1-[[2-chloro-3-(trifluoromethyl)phenyl]acetyl]-6-[(3R,5S)-3,4,5-trimethyl-1-piperazinyl]-, hydrochloride, rel- (9CI) (CA INDEX NAME)

10/089013


Relative stereochemistry.



RN 332399-42-5 CAPLUS

CN 1H-Indole, 6-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-2,3-dihydro-5-methoxy-1-[4-[2-methyl-6-(2-oxo-1-pyrrolidinyl)-3-pyridinyl]benzoyl]-, hydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RE.CNT 6

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/089013

L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2003 ACS

AN 1999:388165 CAPLUS

DN 131:31956

TI Preparation of arylpiperazines and arylpiperidines as combined 5-HT1A, 5-HT1B and 5-HT1D receptor antagonists

IN Gaster, Laramie Mary; Wyman, Paul Adrian

PA SmithKline Beecham PLC, UK

SO PCT Int. Appl., 28 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9929666	A1	19990617	WO 1998-EP7803	19981201
	W: CA, JP, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
PRAI	GB 1997-25931		19971205		
OS	MARPAT 131:31956				
GI					



AB The title compds. [I; Ra = II (wherein A = (un)substituted 5-7 membered carbocyclic ring fused at the 2,3- or 3,4-positions of the adjacent Ph ring, the ring A being optionally fused to a further (un)substituted Ph ring; R2 = halo, alkyl, cycloalkyl, etc.; a = 0-2); L = YC(O)DG, C(O)DG, DGC(O) (Y = NH, NR5 where R5 = alkyl, or Y = CH2, O; D = N, C, CH; G = H, alkyl providing that D = N or CH, or G together with Rb1 forms (CR16R17)t (where t = 2-4 and R16, R17 = H, alkyl), etc.); X = N, C; Rb1, Rb2 = H, halo, OH, etc.; Rc = H, alkyl], useful in the treatment of CNS disorders such as depression, were prepd. Thus, treatment of 5-amino-1-indanone with triphosgene in the presence of Et3N in CH2Cl2 followed by addn. of

5-chloro-6-(4-methylpiperazin-1-yl)indoline afforded 76% III which showed pKi of > 7.5 at 5-HT1A, 5-HT1B and 5-HT1D receptors.


IT 227026-95-1P 227026-96-2P 227026-97-3P  
 227026-98-4P 227026-99-5P 227027-00-1P  
 227027-01-2P 227027-02-3P 227027-03-4P  
 227027-04-5P 227027-05-6P 227027-06-7P  
 227027-07-8P 227027-08-9P 227027-09-0P  
 227027-10-3P 227027-11-4P 227027-12-5P  
 227027-13-6P 227027-14-7P 227027-15-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of arylpiperazines and arylpiperidines as combined 5-HT1A, 5-HT1B and 5-HT1D receptor antagonists)


RN 227026-95-1 CAPLUS

CN 1H-Indole-1-carboxamide, 5-chloro-N-(2,3-dihydro-1-oxo-1H-inden-5-yl)-2,3-dihydro-6-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 227026-96-2 CAPLUS

CN 1H-Indole-1-carboxamide, 5-chloro-2,3-dihydro-6-(4-methyl-1-piperazinyl)-N-(5,6,7,8-tetrahydro-5-oxo-2-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 227026-97-3 CAPLUS


CN 1H-Indole-1-carboxamide, 5-bromo-N-(2,3-dihydro-1-oxo-1H-inden-5-yl)-2,3-dihydro-6-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 227026-98-4 CAPLUS


CN 1H-Indole-1-carboxamide, 5-bromo-2,3-dihydro-6-(4-methyl-1-piperazinyl)-N-(5,6,7,8-tetrahydro-5-oxo-2-naphthalenyl)- (9CI) (CA INDEX NAME)

10/089013



RN 227026-99-5 CAPLUS


CN 1H-Indole-1-carboxamide, 5-bromo-N-(2,3-dihydro-3-oxo-1H-inden-5-yl)-2,3-dihydro-6-(4-methyl-1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 227027-00-1 CAPLUS

CN 1H-Indole-1-carboxamide, 5-chloro-N-(2,3-dihydro-3-oxo-1H-inden-5-yl)-2,3-dihydro-6-(4-methyl-1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 227027-01-2 CAPLUS


CN 1H-Indole-1-carboxamide, 5-bromo-2,3-dihydro-6-(4-methyl-1-piperazinyl)-N-(5,6,7,8-tetrahydro-8-oxo-2-naphthalenyl)-, monohydrochloride (9CI) (CA INDEX NAME)

10/089013




● HCl

RN 227027-02-3 CAPLUS  
CN 1H-Indole-1-carboxamide, 5-chloro-2,3-dihydro-6-(4-methyl-1-piperazinyl)-N-(5,6,7,8-tetrahydro-8-oxo-2-naphthalenyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 227027-03-4 CAPLUS  
CN 1H-Indole-1-carboxamide, 5-chloro-2,3-dihydro-6-(4-methyl-1-piperazinyl)-N-(9-oxo-9H-fluoren-2-yl)- (9CI) (CA INDEX NAME)




RN 227027-04-5 CAPLUS  
CN 1H-Indole-1-carboxamide, 5-chloro-2,3-dihydro-6-(4-methyl-1-piperazinyl)-N-(9-oxo-9H-fluoren-3-yl)- (9CI) (CA INDEX NAME)

10/089013




RN 227027-05-6 CAPLUS

CN 1H-Indole-1-carboxamide, 2,3-dihydro-5-methoxy-6-(4-methyl-1-piperazinyl)-N-(5,6,7,8-tetrahydro-5-oxo-2-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 227027-06-7 CAPLUS

CN 1H-Indole-1-carboxamide, 5-chloro-2,3-dihydro-6-(4-methyl-1-piperazinyl)-N-(5,6,7,8-tetrahydro-5-oxo-1-naphthalenyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 227027-07-8 CAPLUS


CN 1H-Indole-1-carboxamide, 5-bromo-2,3-dihydro-6-(4-methyl-1-piperazinyl)-N-(5,6,7,8-tetrahydro-5-oxo-1-naphthalenyl)-, monohydrochloride (9CI) (CA INDEX NAME)

10/089013




● HCl

RN 227027-08-9 CAPLUS  
CN 1H-Indole-1-carboxamide, 2,3-dihydro-5-methoxy-6-(4-methyl-1-piperazinyl)-  
N-(5,6,7,8-tetrahydro-5-oxo-1-naphthalenyl)-, monohydrochloride (9CI) (CA  
INDEX NAME)



● HCl


RN 227027-09-0 CAPLUS  
CN 1H-Indole-1-carboxamide, 5-bromo-N-(2,3-dihydro-3-oxo-1H-inden-5-yl)-2,3-  
dihydro-6-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 227027-10-3 CAPLUS  
CN 1H-Indole-1-carboxamide, 5-chloro-N-(2,3-dihydro-3-oxo-1H-inden-5-yl)-2,3-


10/089013

dihydro-6-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 227027-11-4 CAPLUS

CN 1H-Indole-1-carboxamide, 5-bromo-2,3-dihydro-6-(4-methyl-1-piperazinyl)-N-(5,6,7,8-tetrahydro-8-oxo-2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 227027-12-5 CAPLUS

CN 1H-Indole-1-carboxamide, 5-chloro-2,3-dihydro-6-(4-methyl-1-piperazinyl)-N-(5,6,7,8-tetrahydro-5-oxo-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 227027-13-6 CAPLUS


CN 1H-Indole-1-carboxamide, 5-chloro-2,3-dihydro-6-(4-methyl-1-piperazinyl)-N-(5,6,7,8-tetrahydro-5-oxo-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 227027-14-7 CAPLUS


CN 1H-Indole-1-carboxamide, 5-bromo-2,3-dihydro-6-(4-methyl-1-piperazinyl)-N-(5,6,7,8-tetrahydro-5-oxo-1-naphthalenyl)- (9CI) (CA INDEX NAME)

10/089013



RN 227027-15-8 CAPLUS

CN 1H-Indole-1-carboxamide, 2,3-dihydro-5-methoxy-6-(4-methyl-1-piperazinyl)-  
N-(5,6,7,8-tetrahydro-5-oxo-1-naphthalenyl)- (9CI) (CA INDEX NAME)





RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/089013

L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2003 ACS  
AN 1998:745030 CAPLUS  
DN 130:13915  
TI Indole derivatives having combined 5HT1A, 5HT1B, and 5HT1D receptor antagonist activity  
IN Gaster, Laramie Mary; Rami, Harshad Kantilal; Wyman, Paul Adrian  
PA Smithkline Beecham PLC, UK  
SO PCT Int. Appl., 119 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9850358	A1	19981112	WO 1998-EP2262	19980414
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	AU 9874310	A1	19981127	AU 1998-74310	19980414
	AU 732863	B2	20010503		
	EP 975593	A1	20000202	EP 1998-921462	19980414
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI			
	JP 2001524116	T2	20011127	JP 1998-547660	19980414
	BR 9809092	A	20020122	BR 1998-9092	19980414
	ZA 9803242	A	19991018	ZA 1998-3242	19980417
	NO 9905065	A	19991015	NO 1999-5065	19991015
	MX 9909583	A	20000331	MX 1999-9583	19991018
PRAI	GB 1997-7829	A	19970418		
	GB 1998-1882	A	19980129		
	WO 1998-EP2262	W	19980414		
OS	MARPAT 130:13915				
GI					



AB The title compds. I [Ra is a group of formula Q, in which P1 is Ph, bicyclic aryl, a 5- to 7-membered heterocyclic ring contg. 1 to 3 heteroatoms selected from oxygen, nitrogen and sulfur, or a bicyclic heterocyclic ring contg. 1 to 3 heteroatoms selected from oxygen, nitrogen and sulfur; R1 = H, halo, C1-6alkyl, C3-6cycloalkyl, COC1-6alkyl,

C1-6alkoxy, hydroxy, hydroxyC1-6alkyl, hydroxyC1-6alkoxy, C1-6alkoxyC1-6alkoxy, C1-6alkanoyl, nitro, trifluoromethyl, cyano, SR9, SOR9, SO2R9, SO2NR10R11, CO2R10, CONR10R11, CO2NR10R11, CONR10(CH2)cCO2R11, (CH2)cNR10R11, (CH2)cCONR10R11, (CH2)cNR10COR11, (CH2)cCO2C1-6alkyl, CO2(CH2)cOR10, NR10R11, NR10CO2R11, NR10CONR10R11, CR10:NOR11, NR10COOR11, CNR10:NOR11, where R10 and R11 are independently hydrogen or C1-6alkyl and c is 1 to 4; R2 = H, halo, C1-6alkyl, C3-6cycloalkyl, C3-6cycloalkenyl, C1-6alkoxy, acyl, aryl, acyloxy, hydroxy, nitro, trifluoromethyl, cyano, CO2R10, CONR10R11, NR10R11 where R10 and R11 are as defined for R1; a is 1, 2 or 3; or Ra is a group contg. bridged rings; Y = NH, alkylamino, CH2, O; V = O, S; D = N, C, CH; W = (CR16R17)t where t = 2-4 and R16 and R17 = H, alkyl, etc.; Rb = H, halo, OH, etc.; Rc = H, alkyl] were prepd. and their 5HT1A,, 5HT1B, and 5HT1D receptor binding detd. E.g., 5-methoxy-6-(4-methylpiperazin-1-yl)indole was treated with KOCMe3, then with 4-bromo-3-methylphenyl isocyanate to give 1-[(4-bromo-3-methylphenyl)aminocarbonyl]-5-methoxy-6-(4-methylpiperazin-1-yl)indole.

IT 216058-19-4P 216058-20-7P 216058-21-8P  
 216058-22-9P 216058-23-0P 216058-24-1P  
 216058-25-2P 216058-26-3P 216058-27-4P  
 216058-28-5P 216058-29-6P 216058-30-9P  
 216058-31-0P 216058-32-1P 216058-33-2P  
 216058-34-3P 216058-35-4P 216058-36-5P  
 216058-37-6P 216058-38-7P 216058-39-8P  
 216058-40-1P 216058-41-2P 216058-42-3P  
 216058-43-4P 216058-45-6P 216058-46-7P  
 216058-47-8P 216058-48-9P 216058-49-0P  
 216058-53-6P 216058-54-7P 216058-55-8P  
 216058-56-9P 216058-57-0P 216058-58-1P  
 216058-59-2P 216058-60-5P 216058-61-6P  
 216058-62-7P 216058-63-8P 216058-64-9P  
 216058-65-0P 216058-66-1P 216058-67-2P  
 216058-68-3P 216058-69-4P 216058-70-7P  
 216058-71-8P 216058-72-9P 216058-73-0P  
 216058-74-1P 216058-75-2P 216058-76-3P  
 216058-77-4P 216058-78-5P 216058-79-6P  
 216058-80-9P 216058-81-0P 216058-82-1P  
 216058-83-2P 216058-84-3P 216058-85-4P  
 216058-86-5P 216058-87-6P 216058-88-7P  
 216058-89-8P 216058-90-1P 216058-91-2P  
 216058-92-3P 216058-93-4P 216058-94-5P  
 216058-95-6P 216058-96-7P 216058-97-8P  
 216058-98-9P 216058-99-0P 216059-00-6P  
 216059-01-7P 216059-02-8P 216059-03-9P  
 216059-04-0P 216059-05-1P 216059-06-2P  
 216059-07-3P 216059-08-4P 216059-09-5P  
 216059-10-8P 216059-11-9P 216059-12-0P  
 216059-13-1P 216059-14-2P 216059-15-3P  
 216059-16-4P 216059-17-5P 216059-18-6P  
 216059-19-7P 216059-20-0P 216059-21-1P  
 216059-22-2P 216059-23-3P 216059-24-4P  
 216059-25-5P 216059-26-6P 216059-27-7P  
 216059-28-8P 216059-29-9P 216059-32-4P  
 216059-33-5P 216059-34-6P 216059-35-7P  
 216059-36-8P 216059-37-9P 216059-38-0P  
 216059-39-1P 216059-40-4P 216059-41-5P  
 216059-42-6P 216059-43-7P 216059-44-8P  
 216059-45-9P 216059-46-0P 216059-47-1P  
 216059-48-2P 216059-49-3P 216059-50-6P  
 216059-51-7P 216059-52-8P 216059-53-9P

10/089013


216059-57-3P 216059-58-4P 216059-59-5P  
216059-60-8P 216059-61-9P 216059-62-0P  
216059-63-1P 216059-64-2P 216060-67-2P  
216060-68-3P 216060-69-4P 216060-70-7P  
216060-71-8P 216060-72-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses).

(prepn. of indole derivs. having combined 5HT1A, 5HT1B, and 5HT1D receptor antagonist activity)


RN 216058-19-4 CAPLUS

CN 1H-Indole-1-carboxamide, N-(4-bromo-3-methylphenyl)-5-methoxy-6-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 216058-20-7 CAPLUS

CN 1H-Indole-1-carboxamide, N-(4-bromo-3-methylphenyl)-2,3-dihydro-5-methoxy-6-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 216058-21-8 CAPLUS


CN 1H-Indole-1-carboxamide, N-(2,3-dichlorophenyl)-2,3-dihydro-5-methoxy-6-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 216058-22-9 CAPLUS


CN 1H-Indole-1-carboxamide, 2,3-dihydro-5-methoxy-6-(4-methyl-1-piperazinyl)-N-[4-(4-pyridinyl)-1-naphthalenyl]- (9CI) (CA INDEX NAME)

10/089013




RN 216058-23-0 CAPLUS

CN 1H-Indole-1-carboxamide, 2,3-dihydro-5-methoxy-6-(4-methyl-1-piperazinyl)-N-[5-(4-pyridinyl)-1-naphthalenyl]- (9CI) (CA INDEX NAME)



RN 216058-24-1 CAPLUS


CN 1H-Indole-1-carboxamide, N-[2,3-dichloro-4-(4-pyridinyl)phenyl]-2,3-dihydro-5-methoxy-6-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 216058-25-2 CAPLUS


CN 1H-Indole-1-carboxamide, 2,3-dihydro-5-methoxy-6-(4-methyl-1-piperazinyl)-N-5-quinolinyl- (9CI) (CA INDEX NAME)

10/089013




RN 216058-26-3 CAPLUS

CN 1H-Indole-1-carboxamide, 2,3-dihydro-6-(4-methyl-1-piperazinyl)-N-[4-(4-pyridinyl)-1-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 216058-27-4 CAPLUS

CN 1H-Indole-1-carboxamide, 5-chloro-2,3-dihydro-6-(4-methyl-1-piperazinyl)-N-[4-(4-pyridinyl)-1-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 216058-28-5 CAPLUS

CN 1H-Indole-1-carboxamide, 5-bromo-2,3-dihydro-6-(4-methyl-1-piperazinyl)-N-[4-(4-pyridinyl)-1-naphthalenyl]- (9CI) (CA INDEX NAME)



RN 216058-29-6 CAPLUS


CN 1H-Indole-1-carboxamide, 5-bromo-2,3-dihydro-6-(4-methyl-1-piperazinyl)-N-[4-(4-pyridinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 216058-30-9 CAPLUS


CN 1H-Indole-1-carboxamide, 5-bromo-N-[3-chloro-4-(4-pyridinyl)phenyl]-2,3-dihydro-6-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)

10/089013




RN 216058-31-0 CAPLUS

CN 1H-Indole-1-carboxamide, 2,3-dihydro-5-methyl-6-(4-methyl-1-piperazinyl)-N-[4-(4-pyridinyl)-1-naphthalenyl]- (9CI) (CA INDEX NAME)



RN 216058-32-1 CAPLUS


CN 1H-Indole-1-carboxamide, N-[3-chloro-4-(4-pyridinyl)phenyl]-2,3-dihydro-5-methyl-6-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 216058-33-2 CAPLUS


CN 1H-Indole-1-carboxamide, 5-ethenyl-2,3-dihydro-6-(4-methyl-1-piperazinyl)-N-[4-(4-pyridinyl)-1-naphthalenyl]- (9CI) (CA INDEX NAME)

10/089013




RN 216058-34-3 CAPLUS

CN 1H-Indole-1-carboxamide, 5-ethyl-2,3-dihydro-6-(4-methyl-1-piperazinyl)-N-[4-(4-pyridinyl)-1-naphthalenyl] - (9CI) (CA INDEX NAME)




RN 216058-35-4 CAPLUS

CN 1H-Indole-1-carboxamide, N-[3-chloro-4-(4-pyridinyl)phenyl]-5-ethyl-2,3-dihydro-6-(4-methyl-1-piperazinyl) - (9CI) (CA INDEX NAME)




RN 216058-36-5 CAPLUS

CN 1H-Indole-1-carboxamide, 2,3-dihydro-6-(4-methyl-1-piperazinyl)-N-[4-(4-pyridinyl)-1-naphthalenyl]-5-(trifluoromethyl) - (9CI) (CA INDEX NAME)




RN 216058-37-6 CAPLUS

CN 1H-Indole-1-carboxamide, N-[3-chloro-4-(4-pyridinyl)phenyl]-2,3-dihydro-6-(4-methyl-1-piperazinyl)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 216058-38-7 CAPLUS


CN 1H-Indole, 2,3-dihydro-5-methoxy-6-(4-methyl-1-piperazinyl)-1-[[4-(4-pyridinyl)-1-naphthalenyl]acetyl]- (9CI) (CA INDEX NAME)



RN 216058-39-8 CAPLUS


CN 1H-Indole, 2,3-dihydro-5-methoxy-6-(4-methyl-1-piperazinyl)-1-[[5-(4-pyridinyl)-1-naphthalenyl]acetyl]- (9CI) (CA INDEX NAME)

10/089013



RN 216058-40-1 CAPLUS


CN 1H-Indole, 2,3-dihydro-6-(4-methyl-1-piperazinyl)-1-[[4-(4-pyridinyl)-1-naphthalenyl]acetyl]- (9CI) (CA INDEX NAME)



RN 216058-41-2 CAPLUS


CN 1H-Indole, 5-chloro-2,3-dihydro-6-(4-methyl-1-piperazinyl)-1-[[4-(4-pyridinyl)-1-naphthalenyl]acetyl]- (9CI) (CA INDEX NAME)

10/089013



RN 216058-42-3 CAPLUS


CN 1H-Indole, 5-bromo-2,3-dihydro-6-(4-methyl-1-piperazinyl)-1-[[4-(4-pyridinyl)-1-naphthalenyl]acetyl]- (9CI) (CA INDEX NAME)



RN 216058-43-4 CAPLUS


CN 1H-Indole, 5-ethenyl-2,3-dihydro-6-(4-methyl-1-piperazinyl)-1-[[4-(4-pyridinyl)-1-naphthalenyl]acetyl]- (9CI) (CA INDEX NAME)

10/089013




RN 216058-45-6 CAPLUS

CN 1H-Indole-1-carboxamide, 5-chloro-2,3-dihydro-6-(4-methyl-1-piperazinyl)-N-[5-(4-pyridinyl)-1-naphthalenyl] - (9CI) (CA INDEX NAME)




RN 216058-46-7 CAPLUS

CN 1H-Indole-1-carboxamide, 5-bromo-2,3-dihydro-6-(4-methyl-1-piperazinyl)-N-[5-(4-pyridinyl)-1-naphthalenyl] - (9CI) (CA INDEX NAME)




RN 216058-47-8 CAPLUS

CN 1H-Indole-1-carboxamide, 2,3-dihydro-5-methoxy-6-(4-methyl-1-piperazinyl)-N-6-quinolinyl- (9CI) (CA INDEX NAME)




RN 216058-48-9 CAPLUS

CN Carbamic acid, [4-[[[5-chloro-2,3-dihydro-6-(4-methyl-1-piperazinyl)-1H-indol-1-yl]carbonyl]amino]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 216058-49-0 CAPLUS

CN 1H-Indole-1-carboxamide, 5-bromo-2,3-dihydro-6-(4-methyl-1-piperazinyl)-N-6-quinolinyl- (9CI) (CA INDEX NAME)




RN 216058-53-6 CAPLUS

CN 1H-Indole-1-carboxamide, 5-chloro-2,3-dihydro-6-(4-methyl-1-piperazinyl)-N-


10/089013

6-quinolinyl- (9CI) (CA INDEX NAME)




RN 216058-54-7 CAPLUS

CN 1H-Indole-1-carboxamide, 5-chloro-2,3-dihydro-6-(4-methyl-1-piperazinyl)-N-(3-phenoxyphenyl)- (9CI) (CA INDEX NAME)




RN 216058-55-8 CAPLUS

CN 1H-Indole-1-carboxamide, 5-chloro-2,3-dihydro-6-(4-methyl-1-piperazinyl)-N-[4-(2-pyrimidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 216058-56-9 CAPLUS


CN 1H-Indole-1-carboxamide, N-(3-benzoylphenyl)-5-chloro-2,3-dihydro-6-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 216058-57-0 CAPLUS


CN 1H-Indole-1-carboxamide, N-(4-benzoylphenyl)-5-chloro-2,3-dihydro-6-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)

10/089013




RN 216058-58-1 CAPLUS

CN 1H-Indole-1-carboxamide, 5-chloro-2,3-dihydro-6-(4-methyl-1-piperazinyl)-N-(2-methyl-6-quinolinyl)- (9CI) (CA INDEX NAME)




RN 216058-59-2 CAPLUS

CN 1H-Indole-1-carboxamide, 5-chloro-N-[4-(2-furanyl)phenyl]-2,3-dihydro-6-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 216058-60-5 CAPLUS


CN 1H-Indole-1-carboxamide, 5-chloro-N-[4-(2-thienyl)phenyl]-2,3-dihydro-6-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 216058-61-6 CAPLUS


CN 1H-Indole, 5-chloro-2,3-dihydro-6-(4-methyl-1-piperazinyl)-1-[[5-(4-pyridinyl)-1-naphthalenyl]acetyl]- (9CI) (CA INDEX NAME)

10/089013




RN 216058-62-7 CAPLUS

CN 1H-Indole, 5-bromo-2,3-dihydro-6-(4-methyl-1-piperazinyl)-1-[[5-(4-pyridinyl)-1-naphthalenyl]acetyl]- (9CI) (CA INDEX NAME)




RN 216058-63-8 CAPLUS

CN 1H-Indole-1-carboxamide, 5-chloro-2,3-dihydro-6-(4-methyl-1-piperazinyl)-N-[4-(1-methyl-4-piperidinyl)-1-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 216058-64-9 CAPLUS

CN 1H-Indole-1-carboxamide, 5-chloro-2,3-dihydro-N-[4-(2-methyl-4-oxazolyl)phenyl]-6-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 216058-65-0 CAPLUS

CN 1H-Indole-1-carboxamide, 5-bromo-2,3-dihydro-6-(4-methyl-1-piperazinyl)-N-[4-(2-methyl-4-pyridinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 216058-66-1 CAPLUS


CN 1H-Indole-1-carboxamide, 5-chloro-2,3-dihydro-6-(4-methyl-1-piperazinyl)-N-[4-(2-methyl-4-pyridinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 216058-67-2 CAPLUS


CN 1H-Indole-1-carboxamide, 5-chloro-N-[4-(2,6-dimethyl-4-pyridinyl)phenyl]-2,3-dihydro-6-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)

10/089013




RN 216058-68-3 CAPLUS

CN 1H-Indole-1-carboxamide, 5-bromo-N-[4-(2,6-dimethyl-4-pyridinyl)phenyl]-2,3-dihydro-6-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 216058-69-4 CAPLUS

CN 1H-Indole-1-carboxamide, N-[4-(2,6-dimethyl-4-pyridinyl)phenyl]-2,3-dihydro-5-methoxy-6-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 216058-70-7 CAPLUS


CN 1H-Indole-1-carboxamide, 5-chloro-N-[4-(2,6-dimethyl-3-pyridinyl)phenyl]-2,3-dihydro-6-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 216058-71-8 CAPLUS


CN 1H-Indole-1-carboxamide, 5-bromo-N-[4-(2,6-dimethyl-3-pyridinyl)phenyl]-2,3-dihydro-6-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)

10/089013




RN 216058-72-9 CAPLUS

CN 1H-Indole-1-carboxamide, N-[4-(2,6-dimethyl-3-pyridinyl)phenyl]-2,3-dihydro-5-methoxy-6-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 216058-73-0 CAPLUS

CN 1H-Indole-1-carboxamide, 5-chloro-2,3-dihydro-N-[4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-6-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 216058-74-1 CAPLUS

CN 1H-Indole-1-carboxamide, 5-chloro-2,3-dihydro-N-[4-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]-6-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 216058-75-2 CAPLUS


CN 1H-Indole-1-carboxamide, 5-chloro-2,3-dihydro-6-(4-methyl-1-piperazinyl)-N-[3-(2-pyrimidinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)



10/089013


RN 216058-76-3 CAPLUS

CN 1H-Indole-1-carboxamide, 5-chloro-2,3-dihydro-6-(4-methyl-1-piperazinyl)-N-[4-(methyl-2-pyrimidinylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 216058-77-4 CAPLUS

CN 1H-Indole-1-carboxamide, 5-bromo-N-[4-(2-furanyl)phenyl]-2,3-dihydro-6-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 216058-78-5 CAPLUS

CN 1H-Indole-1-carboxamide, 5-chloro-2,3-dihydro-6-(4-methyl-1-piperazinyl)-N-[4-(3-thienyl)phenyl]- (9CI) (CA INDEX NAME)




RN 216058-79-6 CAPLUS

CN 1H-Indole-1-carboxamide, 5-bromo-2,3-dihydro-6-(4-methyl-1-piperazinyl)-N-[4-(2-thiazolyl)phenyl]- (9CI) (CA INDEX NAME)



RN 216058-80-9 CAPLUS


CN 1H-Indole-1-carboxamide, 5-chloro-2,3-dihydro-6-(4-methyl-1-piperazinyl)-N-[4-(2-thiazolyl)phenyl]- (9CI) (CA INDEX NAME)



10/089013


RN 216058-81-0 CAPLUS

CN 1H-Indole-1-carboxamide, N-[4-(5-acetyl-2-thienyl)phenyl]-5-chloro-2,3-dihydro-6-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 216058-82-1 CAPLUS

CN 1H-Indole, 1-[(5-bromo-1-naphthalenyl)acetyl]-5-chloro-2,3-dihydro-6-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 216058-83-2 CAPLUS


CN 1H-Indole-1-carboxamide, 5-chloro-2,3-dihydro-6-(4-methyl-1-piperazinyl)-N-(8-phenyl-5-quinolinyl)- (9CI) (CA INDEX NAME)



RN 216058-84-3 CAPLUS


CN 1H-Indole-1-carboxamide, 5-bromo-2,3-dihydro-6-(4-methyl-1-piperazinyl)-N-(8-phenyl-5-quinolinyl)- (9CI) (CA INDEX NAME)

10/089013




RN 216058-85-4 CAPLUS

CN 1H-Indole-1-carboxamide, 5-chloro-2,3-dihydro-6-(4-methyl-1-piperazinyl)-N-[2-(2-phenylethyl)-6-quinolinyl]- (9CI) (CA INDEX NAME)



RN 216058-86-5 CAPLUS


CN 1H-Indole-1-carboxamide, 5-chloro-2,3-dihydro-6-(4-methyl-1-piperazinyl)-N-[5-(1-methyl-4-piperidinyl)-1-naphthalenyl]- (9CI) (CA INDEX NAME)



RN 216058-87-6 CAPLUS


CN 1H-Indole-1-carboxamide, 5-bromo-2,3-dihydro-N-[4-(4-isoquinolinyl)phenyl]-6-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)

10/089013



RN 216058-88-7 CAPLUS


CN 1H-Indole-1-carboxamide, 5-chloro-2,3-dihydro-N-[4-(4-isoquinolinyl)phenyl]-6-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 216058-89-8 CAPLUS


CN 1H-Indole-1-carboxamide, 5-bromo-2,3-dihydro-6-(4-methyl-1-piperazinyl)-N-[4-(3-quinolinyl)phenyl]- (9CI) (CA INDEX NAME)

10/089013




RN 216058-90-1 CAPLUS

CN 1H-Indole-1-carboxamide, 5-chloro-2,3-dihydro-6-(4-methyl-1-piperazinyl)-N-[4-(3-quinolinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 216058-91-2 CAPLUS

CN 1H-Indole-1-carboxamide, 5-chloro-2,3-dihydro-6-(4-methyl-1-piperazinyl)-N-(1,2,3,4-tetrahydro-2-methyl-7-isoquinolinyl)- (9CI) (CA INDEX NAME)



RN 216058-92-3 CAPLUS


CN 1H-Indole-1-carboxamide, 5-bromo-2,3-dihydro-6-(4-methyl-1-piperazinyl)-N-(1,2,3,4-tetrahydro-2-methyl-7-isoquinolinyl)- (9CI) (CA INDEX NAME)



10/089013


RN 216058-93-4 CAPLUS

CN 1H-Indole-1-carboxamide, 5-bromo-2,3-dihydro-6-(4-methyl-1-piperazinyl)-N-[4-(8-quinolinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 216058-94-5 CAPLUS


CN 1H-Indole-1-carboxamide, 5-chloro-2,3-dihydro-6-(4-methyl-1-piperazinyl)-N-[4-(8-quinolinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 216058-95-6 CAPLUS


CN 1H-Indole-1-carboxamide, 5-chloro-2,3-dihydro-N-[4-(1H-imidazol-1-yl)phenyl]-6-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)

10/089013




RN 216058-96-7 CAPLUS

CN 1H-Indole-1-carboxamide, 5-chloro-2,3-dihydro-6-(4-methyl-1-piperazinyl)-N-[4-(4-pyridinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 216058-97-8 CAPLUS


CN 1H-Indole-1-carboxamide, 2,3-dihydro-5-methoxy-6-(4-methyl-1-piperazinyl)-N-(8-phenyl-5-quinolinyl)- (9CI) (CA INDEX NAME)



RN 216058-98-9 CAPLUS


CN 1H-Indole-1-carboxamide, 5-chloro-2,3-dihydro-6-(4-methyl-1-piperazinyl)-N-(8-phenyl-4-quinolinyl)- (9CI) (CA INDEX NAME)

10/089013



RN 216058-99-0 CAPLUS


CN 1H-Indole-1-carboxamide, 5-bromo-2,3-dihydro-6-(4-methyl-1-piperazinyl)-N-(8-phenyl-4-quinolinyl)- (9CI) (CA INDEX NAME)



RN 216059-00-6 CAPLUS


CN 1H-Indole-1-carboxamide, 2,3-dihydro-5-methoxy-6-(4-methyl-1-piperazinyl)-N-(8-phenyl-4-quinolinyl)- (9CI) (CA INDEX NAME)

10/089013




RN 216059-01-7 CAPLUS

CN 1H-Indole-1-carboxamide, 5-chloro-N-[4-(2,6-dimethyl-4-pyridinyl)-3-methylphenyl]-2,3-dihydro-6-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 216059-02-8 CAPLUS


CN 1H-Indole-1-carboxamide, 5-chloro-2,3-dihydro-N-[3-methyl-4-(6-methyl-2-pyridinyl)phenyl]-6-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 216059-03-9 CAPLUS


CN 1H-Indole-1-carboxamide, 5-bromo-2,3-dihydro-N-[3-methyl-4-(6-methyl-2-pyridinyl)phenyl]-6-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)

10/089013




RN 216059-04-0 CAPLUS

CN 1H-Indole-1-carboxamide, 2,3-dihydro-5-methoxy-N-[3-methyl-4-(6-methyl-2-pyridinyl)phenyl]-6-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 216059-05-1 CAPLUS


CN 1H-Indole-1-carboxamide, 5-chloro-2,3-dihydro-6-(4-methyl-1-piperazinyl)-N-[5-(6-methyl-2-pyridinyl)-1-naphthalenyl]- (9CI) (CA INDEX NAME)



RN 216059-06-2 CAPLUS


CN 1H-Indole-1-carboxamide, 2,3-dihydro-5-methoxy-6-(4-methyl-1-piperazinyl)-N-[5-(6-methyl-2-pyridinyl)-1-naphthalenyl]- (9CI) (CA INDEX NAME)

10/089013



RN 216059-07-3 CAPLUS


CN 1H-Indole-1-carboxamide, 5-chloro-6-(4-ethyl-1-piperazinyl)-2,3-dihydro-N-[4-(4-pyridinyl)-1-naphthalenyl]- (9CI) (CA INDEX NAME)



RN 216059-08-4 CAPLUS


CN 1H-Indole-1-carboxamide, 5-chloro-6-(4-ethyl-1-piperazinyl)-2,3-dihydro-N-[5-(4-pyridinyl)-1-naphthalenyl]- (9CI) (CA INDEX NAME)

10/089013



RN 216059-09-5 CAPLUS

CN 1H-Indole-1-carboxamide, 5-chloro-2,3-dihydro-6-(1-piperazinyl)-N-[4-(4-pyridinyl)-1-naphthalenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 216059-10-8 CAPLUS

CN 1H-Indole-1-carboxamide, 5-chloro-2,3-dihydro-6-(1-piperazinyl)-N-[5-(4-pyridinyl)-1-naphthalenyl]-, monohydrochloride (9CI) (CA INDEX NAME)


10/089013



● HCl


RN 216059-11-9 CAPLUS

CN 1H-Indole-1-carboxamide, 5-chloro-2,3-dihydro-6-(4-methyl-1-piperazinyl)-N-[4-(3-pyridazinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 216059-12-0 CAPLUS

CN 1H-Indole-1-carboxamide, 5-bromo-2,3-dihydro-6-(4-methyl-1-piperazinyl)-N-[4-(3-pyridazinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 216059-13-1 CAPLUS


CN 1H-Indole-1-carboxamide, 5-chloro-2,3-dihydro-6-(4-methyl-1-piperazinyl)-N-(4-pyrazinylphenyl)- (9CI) (CA INDEX NAME)



10/089013


RN 216059-14-2 CAPLUS

CN 1H-Indole-1-carboxamide, 5-bromo-2,3-dihydro-6-(4-methyl-1-piperazinyl)-N-(4-pyrazinylphenyl)- (9CI) (CA INDEX NAME)




RN 216059-15-3 CAPLUS

CN 1H-Indole-1-carboxamide, 5-chloro-2,3-dihydro-6-(4-methyl-1-piperazinyl)-N-(6-phenyl-3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 216059-16-4 CAPLUS

CN 1H-Indole-1-carboxamide, 5-bromo-2,3-dihydro-6-(4-methyl-1-piperazinyl)-N-(6-phenyl-3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 216059-17-5 CAPLUS


CN 1H-Indole-1-carboxamide, 5-chloro-2,3-dihydro-6-(4-methyl-1-piperazinyl)-N-[4-(6-methyl-3-pyridazinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 216059-18-6 CAPLUS


CN 1H-Indole-1-carboxamide, 5-bromo-2,3-dihydro-6-(4-methyl-1-piperazinyl)-N-[4-(6-methyl-3-pyridazinyl)phenyl]- (9CI) (CA INDEX NAME)

10/089013




RN 216059-19-7 CAPLUS

CN 1H-Indole-1-carboxamide, 5-chloro-2,3-dihydro-6-(4-methyl-1-piperazinyl)-N-[4-(3-pyridinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 216059-20-0 CAPLUS

CN 1H-Indole-1-carboxamide, 5-chloro-2,3-dihydro-N-[4-(5-methyl-2-oxazolyl)phenyl]-6-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 216059-21-1 CAPLUS

CN 1H-Indole-1-carboxamide, 2,3-dihydro-5-methoxy-N-[4-(5-methyl-2-oxazolyl)phenyl]-6-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 216059-22-2 CAPLUS


CN 1H-Indole-1-carboxamide, 5-bromo-2,3-dihydro-N-[4-(5-methyl-2-oxazolyl)phenyl]-6-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



10/089013


RN 216059-23-3 CAPLUS

CN 1H-Indole-1-carboxamide, 5-chloro-2,3-dihydro-6-(4-methyl-1-piperazinyl)-N-[4-(1-methyl-1H-pyrazol-4-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 216059-24-4 CAPLUS

CN 1H-Indole-1-carboxamide, 5-bromo-2,3-dihydro-6-(4-methyl-1-piperazinyl)-N-[4-(1-methyl-1H-pyrazol-4-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 216059-25-5 CAPLUS

CN 1H-Indole-1-carboxamide, 5-chloro-N-(4'-cyano-3'-methyl[1,1'-biphenyl]-4-yl)-2,3-dihydro-6-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 216059-26-6 CAPLUS

CN 1H-Indole-1-carboxamide, 5-bromo-N-(4'-cyano-3'-methyl[1,1'-biphenyl]-4-yl)-2,3-dihydro-6-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 216059-27-7 CAPLUS

CN 1H-Indole-1-carboxamide, 5-chloro-2,3-dihydro-6-(4-methyl-1-piperazinyl)-N-[4-(6-methyl-3-pyridinyl)phenyl]- (9CI) (CA INDEX NAME)




10/089013




RN 216059-28-8 CAPLUS

CN 1H-Indole-1-carboxamide, 5-bromo-2,3-dihydro-6-(4-methyl-1-piperazinyl)-N-[4-(6-methyl-3-pyridinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 216059-29-9 CAPLUS

CN 1H-Indole-1-carboxamide, 5-chloro-2,3-dihydro-N-[5-(5-methyl-1,2,4-oxadiazol-3-yl)-1-naphthalenyl]-6-(4-methyl-1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 216059-32-4 CAPLUS

CN 1H-Indole-1-carboxamide, 5-chloro-2,3-dihydro-N-[5-(5-methyl-2-oxazolyl)-1-naphthalenyl]-6-(4-methyl-1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)


10/089013



● HCl

RN 216059-33-5 CAPLUS

CN 1H-Indole-1-carboxamide, 2,3-dihydro-5-methoxy-N-[5-(5-methyl-2-oxazolyl)-1-naphthalenyl]-6-(4-methyl-1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 216059-34-6 CAPLUS


CN 1H-Indole-1-carboxamide, 5-bromo-2,3-dihydro-6-(4-methyl-1-piperazinyl)-N-[3-methyl-4-(2-pyrimidinyl)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

10/089013




● HCl

RN 216059-35-7 CAPLUS  
CN 1H-Indole-1-carboxamide, 2,3-dihydro-5-methoxy-6-(4-methyl-1-piperazinyl)-N-[3-methyl-4-(2-pyrimidinyl)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 216059-36-8 CAPLUS  
CN 1H-Indole-1-carboxamide, 5-chloro-2,3-dihydro-6-(4-methyl-1-piperazinyl)-N-[3-methyl-4-(2-pyrimidinyl)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 216059-37-9 CAPLUS  
CN 1H-Indole-1-carboxamide, 5-bromo-2,3-dihydro-6-(4-methyl-1-piperazinyl)-N-[3-methyl-4-(5-pyrimidinyl)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

10/089013




● HCl

RN 216059-38-0 CAPLUS  
CN 1H-Indole-1-carboxamide, 5-chloro-2,3-dihydro-6-(4-methyl-1-piperazinyl)-N-[3-methyl-4-(5-pyrimidinyl)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 216059-39-1 CAPLUS  
CN 1H-Indole-1-carboxamide, 2,3-dihydro-5-methoxy-6-(4-methyl-1-piperazinyl)-N-[3-methyl-4-(5-pyrimidinyl)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 216059-40-4 CAPLUS  
CN 1H-Indole-1-carboxamide, 5-bromo-N-[4-(2,6-dimethyl-4-pyridinyl)-3-methylphenyl]-2,3-dihydro-6-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)

10/089013




RN 216059-41-5 CAPLUS

CN 1H-Indole-1-carboxamide, N-[4-(2,6-dimethyl-4-pyridinyl)-3-methylphenyl]-2,3-dihydro-5-methoxy-6-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 216059-42-6 CAPLUS


CN 1H-Indole-1-carboxamide, 5-chloro-N-[5-(2,6-dimethyl-4-pyridinyl)-1-naphthalenyl]-2,3-dihydro-6-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 216059-43-7 CAPLUS


CN 1H-Indole-1-carboxamide, 5-bromo-N-[5-(2,6-dimethyl-4-pyridinyl)-1-naphthalenyl]-2,3-dihydro-6-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)

10/089013




RN 216059-44-8 CAPLUS

CN 1H-Indole-1-carboxamide, N-[5-(2,6-dimethyl-4-pyridinyl)-1-naphthalenyl]-2,3-dihydro-5-methoxy-6-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 216059-45-9 CAPLUS


CN 1H-Indole-1-carboxamide, N-[4-(2,6-dimethyl-3-pyridinyl)-3-methylphenyl]-2,3-dihydro-5-methoxy-6-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 216059-46-0 CAPLUS


CN 1H-Indole-1-carboxamide, 5-bromo-2,3-dihydro-6-(4-methyl-1-piperazinyl)-N-[3-methyl-4-(2-thiazolyl)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

10/089013




● HCl

RN 216059-47-1 CAPLUS  
CN 1H-Indole-1-carboxamide, 5-chloro-2,3-dihydro-6-(4-methyl-1-piperazinyl)-N-[3-methyl-4-(2-thiazolyl)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 216059-48-2 CAPLUS  
CN 1H-Indole-1-carboxamide, 2,3-dihydro-5-methoxy-6-(4-methyl-1-piperazinyl)-N-[3-methyl-4-(2-thiazolyl)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 216059-49-3 CAPLUS  
CN 1H-Indole-1-carboxamide, N-(5-acetyl-1-naphthalenyl)-5-chloro-2,3-dihydro-6-(4-methyl-1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)


10/089013



● HCl

RN 216059-50-6 CAPLUS

CN 1H-Indole-1-carboxamide, 5-chloro-2,3-dihydro-6-(4-methyl-1-piperazinyl)-N-[5-(2-pyrimidinyl)-1-naphthalenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 216059-51-7 CAPLUS


CN 1H-Indole-1-carboxamide, 5-chloro-2,3-dihydro-6-(4-methyl-1-piperazinyl)-N-[5-(5-pyrimidinyl)-1-naphthalenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

10/089013



● HCl


RN 216059-52-8 CAPLUS  
CN 1H-Indole-1-carboxamide, 2,3-dihydro-5-methoxy-6-(4-methyl-1-piperazinyl)-N-[5-(5-pyrimidinyl)-1-naphthalenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 216059-53-9 CAPLUS  
CN 1H-Indole-1-carboxamide, 5-chloro-N-(5-cyano-1-naphthalenyl)-2,3-dihydro-6-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)

10/089013




RN 216059-57-3 CAPLUS

CN 1H-Indole-1-carboxamide, 5-chloro-2,3-dihydro-N-[5-(5-methyl-2-oxazolyl)-1-naphthalenyl]-6-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 216059-58-4 CAPLUS

CN 1H-Indole-1-carboxamide, 2,3-dihydro-5-methoxy-N-[5-(5-methyl-2-oxazolyl)-1-naphthalenyl]-6-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 216059-59-5 CAPLUS

CN 1H-Indole-1-carboxamide, 5-bromo-2,3-dihydro-6-(4-methyl-1-piperazinyl)-N-[3-methyl-4-(2-pyrimidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 216059-60-8 CAPLUS

CN 1H-Indole-1-carboxamide, 2,3-dihydro-5-methoxy-6-(4-methyl-1-piperazinyl)-N-[3-methyl-4-(2-pyrimidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 216059-61-9 CAPLUS

CN 1H-Indole-1-carboxamide, 5-chloro-2,3-dihydro-6-(4-methyl-1-piperazinyl)-N-[3-methyl-4-(2-pyrimidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 216059-62-0 CAPLUS

CN 1H-Indole-1-carboxamide, 5-bromo-2,3-dihydro-6-(4-methyl-1-piperazinyl)-N-[3-methyl-4-(2-pyrimidinyl)phenyl]- (9CI) (CA INDEX NAME)


10/089013

[3-methyl-4-(5-pyrimidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 216059-63-1 CAPLUS

CN 1H-Indole-1-carboxamide, 5-chloro-2,3-dihydro-6-(4-methyl-1-piperazinyl)-N-[3-methyl-4-(5-pyrimidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 216059-64-2 CAPLUS


CN 1H-Indole-1-carboxamide, 2,3-dihydro-5-methoxy-6-(4-methyl-1-piperazinyl)-N-[3-methyl-4-(5-pyrimidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 216060-67-2 CAPLUS


CN 1H-Indole-1-carboxamide, 5-chloro-2,3-dihydro-N-[5-(3-methyl-1,2,4-oxadiazol-5-yl)-1-naphthalenyl]-6-(4-methyl-1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

10/089013



● HCl


RN 216060-68-3 CAPLUS  
CN 1H-Indole-1-carboxamide, 2,3-dihydro-5-methoxy-N-[5-(3-methyl-1,2,4-oxadiazol-5-yl)-1-naphthalenyl]-6-(4-methyl-1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 216060-69-4 CAPLUS  
CN 1H-Indole-1-carboxamide, 5-bromo-2,3-dihydro-N-[5-(3-methyl-1,2,4-oxadiazol-5-yl)-1-naphthalenyl]-6-(4-methyl-1-piperazinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

10/089013




● HCl

RN 216060-70-7 CAPLUS  
CN 1H-Indole-1-carboxamide, 5-chloro-2,3-dihydro-N-[5-(3-methyl-1,2,4-oxadiazol-5-yl)-1-naphthalenyl]-6-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 216060-71-8 CAPLUS  
CN 1H-Indole-1-carboxamide, 2,3-dihydro-5-methoxy-N-[5-(3-methyl-1,2,4-oxadiazol-5-yl)-1-naphthalenyl]-6-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)

10/089013



RN 216060-72-9 CAPLUS

CN 1H-Indole-1-carboxamide, 5-bromo-2,3-dihydro-N-[5-(3-methyl-1,2,4-oxadiazol-5-yl)-1-naphthalenyl]-6-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



IT 216059-85-7P 216060-20-7P 216060-21-8P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of indole derivs. having combined 5HT1A, 5HT1B, and 5HT1D receptor antagonist activity)

RN 216059-85-7 CAPLUS


CN 1H-Indole-1-carboxamide, 5-chloro-2,3-dihydro-N-(4-iodophenyl)-6-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)

10/089013




RN 216060-20-7 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[5-chloro-2,3-dihydro-1-[[[4-(4-pyridinyl)-1-naphthalenyl]amino]carbonyl]-1H-indol-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 216060-21-8 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[5-chloro-2,3-dihydro-1-[[[5-(4-pyridinyl)-1-naphthalenyl]amino]carbonyl]-1H-indol-6-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RE.CNT 6

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/089013

10/089013

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2003 ACS  
AN 1998:709065 CAPLUS  
DN 129:330740  
TI Preparation of bicyclic aryl or bicyclic heterocyclic ring containing  
(4-methylpiperazin-1-yl)phenyl compounds having a combined 5HT1A, 5HT1B  
and 5HT1D receptor antagonistic activity  
IN Gaster, Laramie Mary; Wyman, Paul Adrian  
PA Smithkline Beecham PLC, UK  
SO PCT Int. Appl., 42 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9847885	A1	19981029	WO 1998-EP2265	19980414
	W: CA, JP, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 975614	A1	20000202	EP 1998-919278	19980414
	R: BE, CH, DE, ES, FR, GB, IT, LI, NL				
	JP 2001526643	T2	20011218	JP 1998-544988	19980414
	US 6159979	A	20001212	US 1999-403149	19991015
PRAI	GB 1997-7876	A	19970418		
	GB 1998-1635	A	19980126		
	WO 1998-EP2265	W	19980414		
OS	MARPAT 129:330740				
GI					

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*


AB The title compds. [I; R1 = II, III (P1 = bicyclic aryl, bicyclic heterocyclic ring contg. 1-3 heteroatoms selected from O, N and S; P2, P3 = Ph, bicyclic aryl, 5-7 membered heterocyclic ring contg. 1-3 heteroatoms selected from O, N and S, or bicyclic heterocyclic group contg. 1-3 heteroatoms selected from O, N or S, providing that at least one of P2 and P3 = bicyclic aryl or bicyclic heterocyclic group; R11 = H, halo, C1-6 alkyl, etc.; R12, R13 = H, halo, C1-6 alkyl, etc.; a, b = 1-3; A = a bond, O, CH2, etc.); L = C(V)DG, DGC(V), YC(V)DG1; V = O, S; D = N, C, CH; G and G1 = H, C1-6 alkyl; Y = NH, NR5 (wherein R5 = C1-6 alkyl), CH2, O; X = N, C; R2, R3 = H, halo, OH, etc.; R4 = H, C1-6 alkyl], useful as CNS agents, were prepd. Thus, treatment of 4-(pyridin-4-yl)naphth-1-ylamine with triphosgene in the presence of Et3N in CH2Cl2 followed by the addn. of a soln. of 4-chloro-3-(4-methylpiperazin-1-yl)aniline in CH2Cl2 afforded 27% IV which showed pKi of > 8.0 at 5-HT1A, 5-HT1B and 5HT1D receptors.

IT 215162-87-1P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of bicyclic aryl or bicyclic heterocyclic ring contg. (4-methylpiperazin-1-yl)phenyl compds. having a combined 5HT1A, 5HT1B and 5HT1D receptor antagonistic activity)

RN 215162-87-1 CAPLUS

CN 1H-Indole, 5-bromo-2,3-dihydro-6-(4-methyl-1-piperazinyl)-1-[[5-(4-pyridinyl)-1-naphthalenyl]carbonyl]- (9CI) (CA INDEX NAME)

10/089013




RE.CNT 7

THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT


10/089013

L4 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2003 ACS  
AN 1995:701901 CAPLUS  
DN 123:83390  
TI Preparation of piperazinylindoles and -indolines as 5-HT1d receptor antagonists  
IN Gaster, Laramie Mary; Duckworth, David Malcolm; Jenkins, Sarah Margaret; Wyman, Paul Adrian  
PA SmithKline Beecham PLC, UK  
SO PCT Int. Appl., 24 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9506637	A1	19950309	WO 1994-EP2663	19940809
	W: JP, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 716650	A1	19960619	EP 1994-925447	19940809
	EP 716650	B1	19990324		
	R: BE, CH, DE, FR, GB, IT, LI, NL				
	JP 09502177	T2	19970304	JP 1994-507898	19940809
	JP 3328936	B2	20020930	JP 1995-507898	19940809
	US 5696122	A	19971209	US 1996-605022	19960226
PRAI	GB 1993-18325	A	19930903		
	GB 1993-18337	A	19930903		
	GB 1993-22251	A	19931028		
	GB 1993-22252	A	19931028		
	GB 1993-25753	A	19931216		
	WO 1994-EP2663	W	19940809		
OS	MARPAT 123:83390				
GI					



I



II


AB The title compds. I [R = (un)substituted Ph, biphenyl or a 5 to 7-membered heterocyclic ring contg. 1-3 heteroatoms selected from N, O or S; R3 = H, halo, HO, C1-6 alkoxy or alkyl; n = 1, 2; R4 = H, C1-6 alkyl; B = CHR9CH10, CR9:C10; R9, R10 = H, C1-6 alkyl], 5-HT1d receptor antagonists useful at 1.0-200 mg/2-3 times a day, is described. Thus piperazinylindoline II (R= H), prepd. in 3 steps from 4-methoxy-3-(4-methyl-1-piperazinyl)benzenamine and acetaldehyde, was acylated with a benzoyl chloride to give benzoylindoline II (R = 4-bromo-3-methylbenzoyl).

IT 165381-72-6P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(prepn. of piperazinylindoles and -indolines as 5-HT1d receptor antagonists)

10/089013

RN 165381-72-6 CAPLUS

CN 1H-Indole, 1-(4-bromo-3-methylbenzoyl)-2,3-dihydro-5-methoxy-6-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



IT 165381-73-7P 165381-74-8P 165381-75-9P

165381-76-0P 165381-77-1P 165381-78-2P


165381-79-3P 165381-80-6P

RL: SPN (Synthetic preparation); PREP (Preparation)

(prepn. of piperazinylindoles and -indolines as 5-HT1d receptor antagonists)

RN 165381-73-7 CAPLUS


CN 1H-Indole, 2,3-dihydro-5-methoxy-6-(4-methyl-1-piperazinyl)-1-[3-methyl-4-(4-pyridinyl)benzoyl]- (9CI) (CA INDEX NAME)



RN 165381-74-8 CAPLUS


CN 1H-Indole, 1-(4-bromo-3-methylbenzoyl)-5-methoxy-6-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)

10/089013




RN 165381-75-9 CAPLUS

CN 1H-Indole, 1-[(5-bromo-4-methoxy-3-thienyl)carbonyl]-2,3-dihydro-5-methoxy-6-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 165381-76-0 CAPLUS

CN 1H-Indole, 2,3-dihydro-5-methoxy-6-(4-methyl-1-piperazinyl)-1-(4-phenoxybenzoyl)- (9CI) (CA INDEX NAME)




RN 165381-77-1 CAPLUS

CN 1H-Indole, 2,3-dihydro-5-methoxy-1-[[2'-methyl-4'-(5-methyl-1,2,4-


10/089013

oxadiazol-3-yl) [1,1'-biphenyl]-4-yl]carbonyl]-6-(4-methyl-1-piperazinyl)-  
(9CI) (CA INDEX NAME)



RN 165381-78-2 CAPLUS


CN 1H-Indole, 5-methoxy-1-[[2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl) [1,1'-  
biphenyl]-4-yl]carbonyl]-6-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX  
NAME)



10/089013

RN 165381-79-3 CAPLUS


CN 1H-Indole, 2,3-dihydro-5-methoxy-1-[[2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)[1,1'-biphenyl]-4-yl]carbonyl]-6-(1-piperazinyl)- (9CI)  
(CA INDEX NAME)



RN 165381-80-6 CAPLUS

CN 1H-Indole, 2,3-dihydro-5-methoxy-1-[[2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)[1,1'-biphenyl]-4-yl]carbonyl]-6-(1-piperazinyl)-, hydrochloride (9CI) (CA INDEX NAME)

10/089013



10/089013

=> file caold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	49.91	198.67
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-9.11	-9.11

FILE 'CAOLD' ENTERED AT 12:42:16 ON 06 MAY 2003  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966  
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> d his

(FILE 'HOME' ENTERED AT 12:39:15 ON 06 MAY 2003)

FILE 'REGISTRY' ENTERED AT 12:39:50 ON 06 MAY 2003

L1 STRUCTURE UPLOADED  
L2 16 S L1  
L3 281 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 12:40:45 ON 06 MAY 2003

L4 7 S L3

FILE 'CAOLD' ENTERED AT 12:42:16 ON 06 MAY 2003

=> s l3

L5 0 L3

=> log h

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.40	199.07
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-9.11

SESSION WILL BE HELD FOR 60 MINUTES  
STN INTERNATIONAL SESSION SUSPENDED AT 12:42:40 ON 06 MAY 2003